Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol, and isoprenaline.
about
Dose-response study with high-dose inhaled salmeterol in healthy subjects.Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patientsSingle dosing comparison of the relative cardiac beta 1/beta 2 activity of inhaled fenoterol and salbutamol in normal subjectsStudies on the bronchodilator, tremorogenic, cardiovascular and hypokalaemic effects of fenoterol dry powder in asthma.Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81Inhaled beta 2-adrenoceptor agonists in asthma: help or hindrance?Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjectsThe dose-related hyper-and-hypokalaemic effects of salbutamol and its arrhythmogenic potentialThe role of selectivity in determining response to beta 2 agonists.The cardiovascular effects of beta adrenergic agonist drugs administered by nebulisation.An update on the use of indacaterol in patients with COPD.Salmeterol: a novel, long-acting beta 2-agonist.Cardiovascular effects of fenoterol under conditions of hypoxaemiaCardiopulmonary interactions of salbutamol and hypoxaemia in healthy young volunteersDoes tachyphylaxis occur to the non-pulmonary effects of salmeterol?The dose-response effects of terbutaline on the variability, approximate entropy and fractal dimension of heart rate and blood pressure.Enhancement of acute myocardial lesions by asthma drugs in rats.Prevalence of asthma among schoolchildren in Patras, Greece: three surveys over 20 years.The cardiovascular effects of beta adrenergic agonist drugs administered by nebulization.Effects of therapeutic doses of albuterol on beta2-adrenergic receptor density and metabolic changes.Inhibition by fenoterol of human eosinophil functions including beta2-adrenoceptor-independent actions.Asthma deaths in New Zealand: Author's reply.The current debate concerning beta-agonists in asthma: a review.Association of beta2-adrenergic receptor polymorphisms with severe asthmaLack of Evidence for Beta-2 Receptor Selectivity: a Study of Metaproterenol, Fenoterol, Isoproterenol, and Epinephrine in Patients with AsthmaSalbutamol-induced electrophysiological changes show no correlation with electrophysiological changes during hyperinsulinaemic-hypoglycaemic clamp in young people with Type 1 diabetes
P2860
Q28327436-8360152B-1522-4AEE-8A99-C6485EE5DC3BQ28367159-69E2C11A-FD8C-417A-9FE8-F5100E9B27A3Q28369504-E1AD986A-962D-4ADE-96C6-67EF2F59D5F0Q34345856-B7C98770-3708-45EF-BE81-18866357F9E6Q34647199-723FFFE0-E7FB-4BAE-B861-A6D2958D68CEQ35252017-CF5C16CF-767C-4088-AF28-2E742C3B7EDEQ35563595-B79EEEB9-414E-4941-91BE-5DE47032291AQ35874322-33BE5830-F1D6-4899-8D56-C107FC74A1F7Q36528256-A4B24757-398B-4C90-8F75-9148BDC1FAAAQ36723589-749A00F6-1084-44A9-A637-250B90EEF75CQ37808058-E675580F-68EA-4A13-8290-A5E057406DCCQ40620716-0F809275-BFD0-441C-8A75-5EE30FE3C49BQ41147911-FB49EF75-A004-495B-A226-4BF059AC7220Q41850857-AD707534-AA27-478A-A66D-55D6B11D3E76Q41870140-2D21E20D-6A3B-45BD-9E11-0C2A0E60BA0DQ42160302-028F69EE-C5D0-4CE4-A5CE-02B0AE7793F7Q42281799-63AAC951-6F41-4360-AE87-326DA26971E7Q43060092-504C1C0A-3F0E-44F2-AFAD-1DC122EA223CQ43239859-873073D3-518E-4167-A658-03F4D6741B4BQ43546451-E473AF73-9097-40D6-BBA0-AA0586DABBC3Q44230025-8B4F3246-8E9F-419C-BAEB-C5C5ADDAE600Q46133998-2A862A04-74B2-4A7E-B611-80BF6E99B03FQ54942896-5C6CEA8E-64ED-47B1-A3B1-2BB0B6F62D45Q57152685-43BFD969-FCDE-489A-9D54-ED3B16A11FECQ57153435-24B92E5F-8DD5-4BCE-B795-A5952153379AQ57412757-0CF97045-0FAA-42D8-B85F-F4E3E225E15B
P2860
Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol, and isoprenaline.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
Cardiovascular and hypokalaemi ...... , fenoterol, and isoprenaline.
@ast
Cardiovascular and hypokalaemi ...... , fenoterol, and isoprenaline.
@en
type
label
Cardiovascular and hypokalaemi ...... , fenoterol, and isoprenaline.
@ast
Cardiovascular and hypokalaemi ...... , fenoterol, and isoprenaline.
@en
prefLabel
Cardiovascular and hypokalaemi ...... , fenoterol, and isoprenaline.
@ast
Cardiovascular and hypokalaemi ...... , fenoterol, and isoprenaline.
@en
P2860
P356
P1433
P1476
Cardiovascular and hypokalaemi ...... , fenoterol, and isoprenaline.
@en
P2093
P2860
P304
P356
10.1136/THX.44.2.136
P407
P577
1989-02-01T00:00:00Z